These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

1067 related articles for article (PubMed ID: 28212992)

  • 21. Change in serum KL-6 level from baseline is useful for predicting life-threatening EGFR-TKIs induced interstitial lung disease.
    Kawase S; Hattori N; Ishikawa N; Horimasu Y; Fujitaka K; Furonaka O; Isobe T; Miyoshi S; Hamada H; Yamane T; Yokoyama A; Kohno N
    Respir Res; 2011 Jul; 12(1):97. PubMed ID: 21791074
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Low forced vital capacity predicts cytotoxic chemotherapy-associated acute exacerbation of interstitial lung disease in patients with lung cancer.
    Enomoto Y; Inui N; Kato T; Baba T; Karayama M; Nakamura Y; Ogura T; Suda T
    Lung Cancer; 2016 Jun; 96():63-7. PubMed ID: 27133752
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Development of psoriatic arthritis during nivolumab therapy for metastatic non-small cell lung cancer, clinical outcome analysis and review of the literature.
    Ruiz-Bañobre J; Pérez-Pampín E; García-González J; Gómez-Caamaño A; Barón-Duarte FJ; López-López R; Vázquez-Rivera F
    Lung Cancer; 2017 Jun; 108():217-221. PubMed ID: 28625638
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Nivolumab versus Docetaxel in Advanced Squamous-Cell Non-Small-Cell Lung Cancer.
    Brahmer J; Reckamp KL; Baas P; Crinò L; Eberhardt WE; Poddubskaya E; Antonia S; Pluzanski A; Vokes EE; Holgado E; Waterhouse D; Ready N; Gainor J; Arén Frontera O; Havel L; Steins M; Garassino MC; Aerts JG; Domine M; Paz-Ares L; Reck M; Baudelet C; Harbison CT; Lestini B; Spigel DR
    N Engl J Med; 2015 Jul; 373(2):123-35. PubMed ID: 26028407
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Nivolumab in the treatment of metastatic squamous non-small cell lung cancer: a review of the evidence.
    Lim JS; Soo RA
    Ther Adv Respir Dis; 2016 Oct; 10(5):444-54. PubMed ID: 27480166
    [TBL] [Abstract][Full Text] [Related]  

  • 26. A multicenter, open-label, phase II trial of S-1 plus carboplatin in advanced non-small cell lung cancer patients with interstitial lung disease.
    Hanibuchi M; Kakiuchi S; Atagi S; Ogushi F; Shimizu E; Haku T; Toyoda Y; Azuma M; Kondo M; Kawano H; Otsuka K; Sakaguchi S; Nokihara H; Goto H; Nishioka Y
    Lung Cancer; 2018 Nov; 125():93-99. PubMed ID: 30429044
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Fatal interstitial lung disease associated with oral erlotinib therapy for lung cancer.
    Makris D; Scherpereel A; Copin MC; Colin G; Brun L; Lafitte JJ; Marquette CH
    BMC Cancer; 2007 Aug; 7():150. PubMed ID: 17683587
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Nivolumab for advanced non-small cell lung cancer patients with mild idiopathic interstitial pneumonia: A multicenter, open-label single-arm phase II trial.
    Fujimoto D; Yomota M; Sekine A; Morita M; Morimoto T; Hosomi Y; Ogura T; Tomioka H; Tomii K
    Lung Cancer; 2019 Aug; 134():274-278. PubMed ID: 31182249
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Nivolumab treatment for oesophageal squamous-cell carcinoma: an open-label, multicentre, phase 2 trial.
    Kudo T; Hamamoto Y; Kato K; Ura T; Kojima T; Tsushima T; Hironaka S; Hara H; Satoh T; Iwasa S; Muro K; Yasui H; Minashi K; Yamaguchi K; Ohtsu A; Doki Y; Kitagawa Y
    Lancet Oncol; 2017 May; 18(5):631-639. PubMed ID: 28314688
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Association Between Imaging Findings of Airway Obstruction Adjacent to Lung Tumors and the Onset of Interstitial Lung Disease After Nivolumab.
    Nakahama K; Tamiya A; Isa SI; Taniguchi Y; Shiroyama T; Suzuki H; Inoue T; Tamiya M; Hirashima T; Imamura F; Atagi S
    In Vivo; 2018; 32(4):887-891. PubMed ID: 29936475
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Postmarketing surveillance study of erlotinib in Japanese patients with non-small-cell lung cancer (NSCLC): an interim analysis of 3488 patients (POLARSTAR).
    Nakagawa K; Kudoh S; Ohe Y; Johkoh T; Ando M; Yamazaki N; Seki A; Takemoto S; Fukuoka M
    J Thorac Oncol; 2012 Aug; 7(8):1296-303. PubMed ID: 22610257
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Protective effect of bevacizumab on chemotherapy-related acute exacerbation of interstitial lung disease in patients with advanced non-squamous non-small cell lung cancer.
    Hamada S; Ichiyasu H; Ikeda T; Inaba M; Kashiwabara K; Sadamatsu T; Sato N; Akaike K; Okabayashi H; Saruwatari K; Tomita Y; Saeki S; Hirata N; Yoshinaga T; Fujii K
    BMC Pulm Med; 2019 Apr; 19(1):72. PubMed ID: 30940113
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Nivolumab Exposure-Response Analyses of Efficacy and Safety in Previously Treated Squamous or Nonsquamous Non-Small Cell Lung Cancer.
    Feng Y; Wang X; Bajaj G; Agrawal S; Bello A; Lestini B; Finckenstein FG; Park JS; Roy A
    Clin Cancer Res; 2017 Sep; 23(18):5394-5405. PubMed ID: 28916617
    [No Abstract]   [Full Text] [Related]  

  • 34. Nested case control study of proteomic biomarkers for interstitial lung disease in Japanese patients with non-small-cell lung cancer treated with erlotinib: a multicenter phase IV study (JO21661).
    Atagi S; Katakami N; Yoshioka H; Fukuoka M; Kudoh S; Ogiwara A; Imai M; Ueda M; Matsui S
    Clin Lung Cancer; 2013 Jul; 14(4):407-17. PubMed ID: 23490546
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Nedaplatin plus docetaxel versus cisplatin plus docetaxel for advanced or relapsed squamous cell carcinoma of the lung (WJOG5208L): a randomised, open-label, phase 3 trial.
    Shukuya T; Yamanaka T; Seto T; Daga H; Goto K; Saka H; Sugawara S; Takahashi T; Yokota S; Kaneda H; Kawaguchi T; Nagase S; Oguri T; Iwamoto Y; Nishimura T; Hattori Y; Nakagawa K; Nakanishi Y; Yamamoto N;
    Lancet Oncol; 2015 Dec; 16(16):1630-8. PubMed ID: 26522337
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Discontinuation due to immune-related adverse events is a possible predictive factor for immune checkpoint inhibitors in patients with non-small cell lung cancer.
    Komiya K; Nakamura T; Abe T; Ogusu S; Nakashima C; Takahashi K; Kimura S; Sueoka-Aragane N
    Thorac Cancer; 2019 Sep; 10(9):1798-1804. PubMed ID: 31328416
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Nivolumab Monotherapy for First-Line Treatment of Advanced Non-Small-Cell Lung Cancer.
    Gettinger S; Rizvi NA; Chow LQ; Borghaei H; Brahmer J; Ready N; Gerber DE; Shepherd FA; Antonia S; Goldman JW; Juergens RA; Laurie SA; Nathan FE; Shen Y; Harbison CT; Hellmann MD
    J Clin Oncol; 2016 Sep; 34(25):2980-7. PubMed ID: 27354485
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Nivolumab in never-smokers with advanced squamous non-small cell lung cancer: Results from the Italian cohort of an expanded access program.
    Garassino MC; Crinò L; Catino A; Ardizzoni A; Cortesi E; Cappuzzo F; Bordi P; Calabrò L; Barbieri F; Santo A; Altavilla G; Ambrosio F; Mini E; Vasile E; Morgillo F; Scoppola A; Bengala C; Follador A; Tedde N; Giannarelli D; Lo Russo G; Vitiello F
    Tumour Biol; 2018 Nov; 40(11):1010428318815047. PubMed ID: 30486741
    [TBL] [Abstract][Full Text] [Related]  

  • 39. The ATS/ERS/JRS/ALAT statement "IPF by HRCT" could predict acute exacerbation of interstitial lung disease in non-small cell lung cancer.
    Asai N; Katsuda E; Hamanaka R; Kosaka K; Matsubara A; Nishimura M; Tanaka H; Yokoe N; Takahashi A; Yamaguchi E; Kubo A
    Tumori; 2017 Jan; 103(1):60-65. PubMed ID: 27791236
    [TBL] [Abstract][Full Text] [Related]  

  • 40. FDA Approval Summary: Nivolumab for the Treatment of Metastatic Non-Small Cell Lung Cancer With Progression On or After Platinum-Based Chemotherapy.
    Kazandjian D; Suzman DL; Blumenthal G; Mushti S; He K; Libeg M; Keegan P; Pazdur R
    Oncologist; 2016 May; 21(5):634-42. PubMed ID: 26984449
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 54.